Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CHD9 |
| Gene Name: | CHD9 |
| Protein Full Name: | Chromodomain-helicase-DNA-binding protein 9 |
| Alias: | AD013; ATP-dependent helicase CHD9; BC022889; Chromatin-related mesenchymal modulator; Chromatin-remodeling factor CHROM1; Chromodomain helicase DNA binding protein 9; CReMM; FLJ12178; KIAA0308; KISH2; Kismet homolog 2; Peroxisomal proliferator-activated receptor A-interacting complex 320 kDa protein; PPAR-alpha-interacting complex protein 320 kDa; PRIC320 |
| Mass (Da): | 326022 |
| Number AA: | 2897 |
| UniProt ID: | Q3L8U1 |
| Locus ID: | 80205 |
| COSMIC ID: | CHD9 |
| Gene location on chromosome: | 16q12.2 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19851 |
| Percent of cancer specimens with mutations: | 1.6 |
| Normal role description: | CHD9 is a ATP-dependent chromatin remodelling protein. It also acts as a transcriptional regulator of many nuclear receptors such as PPARA. It is involved in differentiation of progenitors during osteogenesis and skeletal formation. |